Lipid metabolome-wide effects of the PPARγ agonist rosiglitazone

Journal of Lipid Research

Volumn 43, Issue 11, 2002, Pages 1809-1817

  Watkins, Steven M ^a   Reifsnyder, Peter R ^b   Pan, Huei Ju ^b   Bruce German, J ^c   Leiter, Edward H ^b  

^a Lipomics Technologies Inc   (United States)

^b JACKSON LABORATORY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diabetes; Lipid metabolism; Metabolomics; Mouse; Peroxisome proliferator activated receptor ; Steatosis

Indexed keywords

CARDIOLIPIN; FATTY ACID; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CELL RECEPTOR; THIAZOLE DERIVATIVE; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; FATTY ACID SYNTHESIS; FATTY LIVER; FEMALE; HYPOLIPEMIA; LIPID METABOLISM; LIPOGENESIS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PEROXISOME; PHENOTYPE; PRIORITY JOURNAL; TISSUE SPECIFICITY; ADIPOSE TISSUE; ANIMAL; BLOOD; DRUG POTENTIATION; GENE EXPRESSION; HEART; HEART MUSCLE; LIVER; MALE; METABOLISM; MOUSE MUTANT; WEIGHT GAIN;

ADIPOSE TISSUE; ANIMALS; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION; HEART; LIPID METABOLISM; LIPIDS; LIVER; MALE; MICE; MICE, OBESE; MYOCARDIUM; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; WEIGHT GAIN;

EID: 0036846241     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M200169-JLR200     Document Type: Article

References (32)

1. Spiegelman, B. M. 1998. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes. 47: 507-514.
2. Saltiel, A. R., and J. M, Olefsky. 1996. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 45: 1661-1669.
3. Bedoucha, M., E. Atzpodien, and U. A. Boelsterli. 2001. Diabetic KKAy alice mice exhibit increased hepatic PPARgammal gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J. Hepatol. 35: 17-23.
4. Parulkar, A. A., M. L. Pendergrass., R. Granda-Ayala, T. R. Lee, and V. A. Fonseca. 2001. Nonhypoglycemic effects of thiazolidinediones. Ann. Intern. Med. 134: 61-71.
5. Leiter, E. H., P. C. Reifsnyder, K. Flurkey, H. J. Partke, E. Junger, and L. Herberg. 1998. NIDDM genes in mice: Deleterious synergism by both parental genomes contributes to diabetogenic thresholds. Diabetes. 47: 1287-1295.
6. Reifsnyder, P. C., G. Churchill, and E. H. Leiter. 2000. Maternal environment and genotype interact to establish diabesity in mice. Genome Res. 10: 1568-1578.
7. Folch, J., M. Lees, and G. H. Sloane-Stanley. 1957. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226: 497-509.
8. Watkins, S. M., T. Y. Lin, R. M. Davis, J. R. Ching, E. J. DePeters, G. M. Halpern, R. L. Walzem, and J. B. German. 2001. Unique phospholipid metabolism in mouse heart in response to dietary docosahexaenoic or α-linolenic acids. Lipids. 36: 247-254.
9. Nagan, N., and R. Zoeller. 2001. Plasmalogens: Biosynthesis and functions. Prog. Lipid Res. 40: 199-229.
10. Fuchtenbusch, M., E. Standl, and H. Schatz. 2000. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes. 108: 151-163.
11. Gregoire, F. M., Q. Zhang, S. J. Smith, C. Tong, D. Ross, H. Lopez, and D. B. West. 2002. Diet-induced obesity and hepatic gene expression alterations in C57BL/6J and ICAM-1-deficient mice. Am. J. Physiol. Endocrinol. Metab. 282: E703-713.
12. Fujiwara, T., A. Okuno, S. Yoshioka, and H. Horikoshi. 1995. Suppression of hepatic gluconeogenesis in long-term Troglitazone treated diabetic KK and C57BL/KsJ-db/db mice. Metabolism, 44: 486-490.
13. Shimabukuro, M., Y. T. Zhou, Y. Lee, and R. H. Unger. 1998. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J. Biol. Chem. 273: 3547-3550.
14. Memon, R. A., L. H. Tecott, K. Nonogaki, A. Beigneux, A. H. Moser, C. Grunfeld, and K. R. Feingold. 2000. Up-regulation of peroxisome proliferator-activated receptors (PPAR-α) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: Troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology. 141: 4021-4031.
15. Burant, C. E, S. Sreenan, K. Hirano, T. A. Tai, J. Lohmiller, J. Lukens, N. O. Davidson, S. Ross, and R. A. Graves. 1997. Troglitazone action is independent of adipose tissue. J. Clin. Invest. 100: 2900-2908.
16. Daum, G. 1985. Lipids of mitochondria. Biochim. Biophys. Acta. 822: 1-42.
17. Hoch, F. L. 1992. Cardiolipins and biomembrane function. Biochim. Biophys. Acta. 1113: 71-133.
18. Hatch, G. M. 1994. Cardiolipin biosynthesis in the isolated heart. Biochem. J. 297: 201-208.
19. Beleznai, Z., and V. Jancsik. 1989. Role of cardiolipin in the functioning of mitochondrial L-glycerol-3-phosphate dehydrogenase. Biochem. Biophys. Res. Commun. 159: 132-139.
20. Fry, M., and D. E. Green. 1981. Cardiolipin requirement for electron transfer in complex I and III of the mitochondrial respiratory chain. J. Biol. Chem. 256: 1874-1880.
21. Ohtsuka, T., M. Nishijima, K. Suzuki, and Y. Akamatsu. 1993. Mitochondrial dysfunction of a cultured Chinese hamster ovary cell mutant deficient in cardiolipin. J. Biol. Chem. 268: 22914-22919.
22. Watkins, S. M., L. C. Carter, and J. B. German. 1998. Docosahexaenoic acid accumulates in cardiolipin and enhances HT-29 cell oxidant production. J. Lipid Res. 39: 1583-1588.
23. Moore, S. A., E. Hurt, E. Yoder, H. Sprecher, and A. A. Spector. 1995. Reevaluation of the pathways for the biosynthesis of polyun-saturated fatty acids. J. Lipid. Res. 36: 2433-2443.
24. Sprecher, H., D. L. Luthria, B. S. Mohammed, and S. P. Baykousheva. 1995. J. Lipid Res. 36: 2471-2477.
25. Voss, A., M. Reinhart, S. Sankarappa, and H. Sprecher. 1991. The metabolism of 7,10,13,16,19-docosapentaenoic acid to 4,7,10,13, 16,19-docosahexaenoic acid in rat liver is independent of a 4-desaturase. J. Biol. Chem. 266: 19995-20000.
26. Yang, B. C., T. G. Saldeen, J. L. Bryant, W. W. Nichols, and J. L. Mehta. 1993. Long-term dietary fish oil supplementation protects against ischemia-reperfusion-induced myocardial dysfunction in isolated rat hearts. Am. Heart J. 126: 1287-1292.
27. Yang, B., T. G. Saldeen, W. W. Nichols, and J. L. Mehta. 1993. Dietary fish oil supplementation attenuates myocardial dysfunction and injury caused by global ischemia and reperfusion in isolated rat hearts. J. Nutr. 123: 2067-2074.
28. Hock, C. E., L. D. Beck, R. C. Bodine, and D. K. Reibel. 1990. Influence of dietary n-3 fatty acids on myocardial ischemia and reperfusion. Am. J. Physiol. 259: H1518-1526.
29. McLennan, P. L., T. M. Bridle, M. Y. Abeywardena, and J. S. Charnock. 1993. Comparative efficacy of n-3 and n-6 polyunsaturated fatty acids in modulating ventricular fibrillation threshold in marmoset monkeys. Am. J. Clin. Nutr. 58: 666-669.
30. Pepe, S., and P. L. McLennan. 1996. Dietary fish oil confers direct antiarrhythmic properties on the myocardium of rats. J. Nutr. 126: 34-42.
31. Leaf, A. 1995. Omega-3 fatty acids and prevention of ventricular fibrillation. Prostaglandins Leukot. Essent. Fatty Acids. 52: 197-198.
32. Thai, T., C. Rodemer, A. Jauch, A. Hunziker, A. Moser, K. Gorgas, and W. Just. 2001. Impaired membrane traffic in defective ether lipid biosynthesis. Hum. Mol. Genet. 10: 127-136.